New drug MP0533 takes aim at Hard-to-Treat leukemia
NCT ID NCT05673057
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new drug called MP0533 in adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is designed to help the body's immune cells find and attack cancer cells. The study will first find the safest dose and then check if the drug can shrink the cancer. About 249 people will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MP0533 (a drug that helps immune cells attack leukemia cells)
What this could lead to
If this works, it could offer a new treatment option for people with hard-to-treat AML or MDS.
What could go wrong
This is an early (phase 1/2a) trial, so the drug may not work or could have serious side effects. It is only tested in a small number of people.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AP-HP Hôpital Saint-Louis
Paris, 75010, France
-
Amsterdam UMC - Locatie VUmc
Amsterdam, Netherlands
-
CHU Bordeaux
Bordeaux, France
-
Erasmus MC
Rotterdam, Netherlands
-
Groningen UMC
Groningen, Provincie Groningen, Netherlands
-
IUCT Oncopole
Toulouse, France
-
Inselspital, Universitaetsspital Bern
Bern, Canton of Bern, 3010, Switzerland
-
Universitaetsspital Zuerich
Zurich, Canton of Zurich, 8006, Switzerland
-
Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania